Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues.

Bonk S, Kluth M, Hube-Magg C, Polonski A, Soekeland G, Makropidi-Fraune G, Möller-Koop C, Witt M, Luebke AM, Hinsch A, Burandt E, Steurer S, Clauditz TS, Schlomm T, Perez D, Graefen M, Heinzer H, Huland H, Izbicki JR, Wilczak W, Minner S, Sauter G, Simon R.

Oncotarget. 2019 Sep 10;10(52):5439-5453. doi: 10.18632/oncotarget.27145. eCollection 2019 Sep 10.

2.

Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer.

Lebok P, von Hassel A, Meiners J, Hube-Magg C, Simon R, Höflmayer D, Hinsch A, Dum D, Fraune C, Göbel C, Möller K, Sauter G, Jacobsen F, Büscheck F, Prien K, Krech T, Krech RH, von der Assen A, Wölber L, Witzel I, Schmalfeldt B, Geist S, Paluchoswski P, Wilke C, Heilenkötter U, Terracciano L, Müller V, Wilczak W, Burandt EC.

Aging (Albany NY). 2019 Sep 18;11. doi: 10.18632/aging.102287. [Epub ahead of print]

3.

Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers.

Luebke AM, Attarchi-Tehrani A, Meiners J, Hube-Magg C, Lang DS, Kluth M, Tsourlakis MC, Minner S, Simon R, Sauter G, Büscheck F, Jacobsen F, Hinsch A, Steurer S, Schlomm T, Huland H, Graefen M, Haese A, Heinzer H, Clauditz TS, Burandt E, Wilczak W, Höflmayer D.

Cancer Biol Med. 2019 May;16(2):319-330. doi: 10.20892/j.issn.2095-3941.2018.0384.

4.

Expression of the immune checkpoint receptor TIGIT in seminoma.

Hinsch A, Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C, Li W, Makrypidi-Fraune G, Wellge B, Mandelkow T, Debatin NF, Höflmayer D, Lennartz M, Sauter G, Izbicki JR, Minner S, Büscheck F, Uhlig R, Dum D, Krech T, Luebke AM, Wittmer C, Jacobsen F, Burandt E, Steurer S, Wilczak W.

Oncol Lett. 2019 Aug;18(2):1497-1502. doi: 10.3892/ol.2019.10428. Epub 2019 May 31.

5.

Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy.

Minner S, Hager D, Steurer S, Höflmayer D, Tsourlakis MC, Möller-Koop C, Clauditz TS, Hube-Magg C, Luebke AM, Simon R, Sauter G, Göbel C, Weidemann S, Lebok P, Dum D, Fraune C, Izbicki J, Burandt E, Schlomm T, Huland H, Heinzer H, Haese A, Graefen M, Heumann A.

Neoplasia. 2019 Sep;21(9):872-881. doi: 10.1016/j.neo.2019.07.003. Epub 2019 Aug 2.

6.

The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer.

Büscheck F, Zub M, Heumann A, Hube-Magg C, Simon R, Lang DS, Höflmayer D, Neubauer E, Jacobsen F, Hinsch A, Luebke AM, Tsourlakis MC, Sauter G, Huland H, Graefen M, Haese A, Heinzer H, Schlomm T, Clauditz TS, Burandt E, Wilczak W, Steurer S, Minner S.

Tumour Biol. 2019 Jul;41(7):1010428318824815. doi: 10.1177/1010428318824815.

PMID:
31296150
7.

Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder.

Mandelkow T, Blessin NC, Lueerss E, Pott L, Simon R, Li W, Wellge B, Debatin NF, Höflmayer D, Izbicki JR, Büscheck F, Luebke AM, Wittmer C, Jacobsen F, Lutz F, Burandt E, Steurer S, Sauter G, Tsourlakis MC, Wilczak W, Hinsch A, Minner S.

Dis Markers. 2019 May 2;2019:2532518. doi: 10.1155/2019/2532518. eCollection 2019.

8.

SNW1 is a prognostic biomarker in prostate cancer.

Höflmayer D, Willich C, Hube-Magg C, Simon R, Lang D, Neubauer E, Jacobsen F, Hinsch A, Luebke AM, Tsourlakis MC, Huland H, Graefen M, Haese A, Heinzer H, Minner S, Büscheck F, Sauter G, Schlomm T, Steurer S, Clauditz TS, Burandt E, Wilczak W, Bernreuther C.

Diagn Pathol. 2019 May 1;14(1):33. doi: 10.1186/s13000-019-0810-8.

9.

A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer.

Eichenauer T, Hussein M, Hube-Magg C, Kluth M, Büscheck F, Höflmayer D, Tsourlakis MC, Steurer S, Clauditz TS, Luebke AM, Burandt E, Wilczak W, Hinsch A, Dum D, Beyer B, Steuber T, Huland H, Graefen M, Simon R, Sauter G, Melling N, Schlomm T, Minner S.

Oncotarget. 2019 Mar 1;10(18):1729-1744. doi: 10.18632/oncotarget.26739. eCollection 2019 Mar 1.

10.

p53 overexpression is a prognosticator of poor outcome in esophageal cancer.

Melling N, Norrenbrock S, Kluth M, Simon R, Hube-Magg C, Steurer S, Hinsch A, Burandt E, Jacobsen F, Wilczak W, Quaas A, Bockhorn M, Grupp K, Tachezy M, Izbicki J, Sauter G, Gebauer F.

Oncol Lett. 2019 Apr;17(4):3826-3834. doi: 10.3892/ol.2019.10020. Epub 2019 Feb 6.

11.

Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer.

Schroeder C, Grell J, Hube-Magg C, Kluth M, Lang D, Simon R, Höflmayer D, Minner S, Burandt E, Clauditz TS, Büscheck F, Jacobsen F, Huland H, Graefen M, Schlomm T, Sauter G, Steurer S.

BMC Cancer. 2019 Mar 1;19(1):193. doi: 10.1186/s12885-019-5390-1.

12.

Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer.

Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C, Li W, Makrypidi-Fraune G, Wellge B, Mandelkow T, Debatin NF, Höflmayer D, Lennartz M, Sauter G, Izbicki JR, Minner S, Büscheck F, Uhlig R, Dum D, Krech T, Luebke AM, Wittmer C, Jacobsen F, Burandt EC, Steurer S, Wilczak W, Hinsch A.

Dis Markers. 2019 Jan 10;2019:5160565. doi: 10.1155/2019/5160565. eCollection 2019.

13.

5q21 deletion is often heterogeneous in prostate cancer.

Kluth M, Al Kilani Z, Özden C, Hussein K, Frogh S, Möller-Koop C, Burandt E, Steurer S, Büscheck F, Jacobsen F, Luebke AM, Minner S, Tsourlakis MC, Hoeflmayer D, Wittmer C, Schlomm T, Sauter G, Simon R, Wilczak W.

Genes Chromosomes Cancer. 2019 Aug;58(8):509-515. doi: 10.1002/gcc.22730. Epub 2019 Jan 24.

PMID:
30623509
14.

Superficially invasive stage IA vulvar squamous cell carcinoma-therapy and prognosis.

Grimm D, Prieske K, Mathey S, Kuerti S, Burandt E, Schmalfeldt B, Woelber L.

Int J Gynecol Cancer. 2019 Mar;29(3):466-473. doi: 10.1136/ijgc-2018-000046. Epub 2019 Jan 4.

PMID:
30622111
15.

Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma.

Li W, Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C, Makrypidi-Fraune G, Wellge B, Mandelkow T, Debatin NF, Pott L, Höflmayer D, Lennartz M, Sauter G, Izbicki JR, Minner S, Büscheck F, Uhlig R, Dum D, Krech T, Luebke AM, Wittmer C, Jacobsen F, Burandt E, Steurer S, Wilczak W, Hinsch A.

BMC Cancer. 2018 Dec 4;18(1):1209. doi: 10.1186/s12885-018-5111-1.

16.

Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.

Minner S, Lutz J, Hube-Magg C, Kluth M, Simon R, Höflmayer D, Burandt E, Tsourlakis MC, Sauter G, Büscheck F, Wilczak W, Steurer S, Schlomm T, Huland H, Graefen M, Haese A, Heinzer H, Jacobsen F, Hinsch A, Poos A, Oswald M, Rippe K, König R, Schroeder C.

Prostate. 2019 Feb;79(3):302-311. doi: 10.1002/pros.23736. Epub 2018 Nov 14.

PMID:
30430607
17.

Correlation of Isotope Count With Sentinel Node Positivity in Vulvar Cancer.

Woelber L, Joosse SA, Grimm D, Mathey S, Mahner S, Burandt E, Klutmann S, Schmalfeldt B, Prieske K.

Int J Gynecol Cancer. 2018 Sep;28(7):1403-1409. doi: 10.1097/IGC.0000000000001298.

PMID:
29923853
18.

13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer.

Kluth M, Scherzai S, Büschek F, Fraune C, Möller K, Höflmayer D, Minner S, Göbel C, Möller-Koop C, Hinsch A, Neubauer E, Tsourlakis MC, Sauter G, Heinzer H, Graefen M, Wilczak W, Luebke AM, Burandt E, Steurer S, Schlomm T, Simon R.

Genes Chromosomes Cancer. 2018 Oct;57(10):504-512. doi: 10.1002/gcc.22645. Epub 2018 Aug 20.

PMID:
29923647
19.

PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer.

Heinrich MC, Göbel C, Kluth M, Bernreuther C, Sauer C, Schroeder C, Möller-Koop C, Hube-Magg C, Lebok P, Burandt E, Sauter G, Simon R, Huland H, Graefen M, Heinzer H, Schlomm T, Heumann A.

BMC Cancer. 2018 May 31;18(1):612. doi: 10.1186/s12885-018-4547-7.

20.

Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer.

Prieske K, Prieske S, Joosse SA, Trillsch F, Grimm D, Burandt E, Mahner S, Schmalfeldt B, Milde-Langosch K, Oliveira-Ferrer L, Woelber L.

Oncotarget. 2017 Sep 15;8(47):83063-83074. doi: 10.18632/oncotarget.20945. eCollection 2017 Oct 10.

21.

Correction: Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer.

Kluth M, Ahrary R, Hube-Magg C, Ahmed M, Volta H, Schwemin C, Steurer S, Wittmer C, Wilczak W, Burandt E, Krech T, Adam M, Michl U, Heinzer H, Salomon G, Graefen M, Koop C, Minner S, Simon R, Sauter G, Schlomm T.

Oncotarget. 2017 Jan 10;8(2):3761. doi: 10.18632/oncotarget.14557. No abstract available.

22.

MALDI imaging mass spectrometry reveals multiple clinically relevant masses in colorectal cancer using large-scale tissue microarrays.

Hinsch A, Buchholz M, Odinga S, Borkowski C, Koop C, Izbicki JR, Wurlitzer M, Krech T, Wilczak W, Steurer S, Jacobsen F, Burandt EC, Stahl P, Simon R, Sauter G, Schlüter H.

J Mass Spectrom. 2017 Mar;52(3):165-173. doi: 10.1002/jms.3916.

PMID:
28117928
23.

p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer.

Lebok P, Roming M, Kluth M, Koop C, Özden C, Taskin B, Hussein K, Lebeau A, Witzel I, Wölber L, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Müller V, Schmalfeldt B, Simon R, Sauter G, Terracciano L, Krech RH, von der Assen A, Burandt E.

Oncotarget. 2016 Dec 6;7(49):81322-81331. doi: 10.18632/oncotarget.13227.

24.

Male papillary breast cancer treated by wide resection and latissimus dorsi flap reconstruction: A case report and review of the literature.

Banys-Paluchowski M, Burandt E, Banys J, Geist S, Sauter G, Krawczyk N, Paluchowski P.

World J Clin Oncol. 2016 Oct 10;7(5):420-424.

25.

Patterns of distant metastases in vulvar cancer.

Prieske K, Haeringer N, Grimm D, Trillsch F, Eulenburg C, Burandt E, Schmalfeldt B, Mahner S, Mueller V, Woelber L.

Gynecol Oncol. 2016 Sep;142(3):427-34. doi: 10.1016/j.ygyno.2016.07.009. Epub 2016 Jul 9.

PMID:
27401841
26.

Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer.

Lebok P, Huber J, Burandt EC, Lebeau A, Marx AH, Terracciano L, Heilenkötter U, Jänicke F, Müller V, Paluchowski P, Geist S, Wilke C, Simon R, Sauter G, Quaas A.

Mol Med Rep. 2016 Aug;14(2):1443-50. doi: 10.3892/mmr.2016.5430. Epub 2016 Jun 23.

27.

High levels of class III β-tubulin expression are associated with aggressive tumor features in breast cancer.

Lebok P, Öztürk M, Heilenkötter U, Jaenicke F, Müller V, Paluchowski P, Geist S, Wilke C, Burandt E, Lebeau A, Wilczak W, Krech T, Simon R, Sauter G, Quaas A.

Oncol Lett. 2016 Mar;11(3):1987-1994. Epub 2016 Feb 9.

28.

The Risk of Contralateral Non-sentinel Metastasis in Patients with Primary Vulvar Cancer and Unilaterally Positive Sentinel Node.

Woelber L, Eulenburg C, Grimm D, Trillsch F, Bohlmann I, Burandt E, Dieckmann J, Klutmann S, Schmalfeldt B, Mahner S, Prieske K.

Ann Surg Oncol. 2016 Aug;23(8):2508-14. doi: 10.1245/s10434-016-5114-6. Epub 2016 Feb 8.

PMID:
26856721
29.

E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer.

Trillsch F, Kuerti S, Eulenburg C, Burandt E, Woelber L, Prieske K, Eylmann K, Oliveira-Ferrer L, Milde-Langosch K, Mahner S.

Br J Cancer. 2016 Jan 19;114(2):213-20. doi: 10.1038/bjc.2015.436.

30.

Partial PTEN deletion is linked to poor prognosis in breast cancer.

Lebok P, Kopperschmidt V, Kluth M, Hube-Magg C, Özden C, B T, Hussein K, Mittenzwei A, Lebeau A, Witzel I, Wölber L, Mahner S, Jänicke F, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Terracciano L, Krech R, von d Assen A, Müller V, Burandt E.

BMC Cancer. 2015 Dec 16;15:963. doi: 10.1186/s12885-015-1770-3.

31.

Liposarcoma of the breast arising in a malignant phyllodes tumor: A case report and review of the literature.

Banys-Paluchowski M, Burandt E, Quaas A, Wilczak W, Geist S, Sauter G, Krawczyk N, Pietzner K, Paluchowski P.

World J Clin Oncol. 2015 Oct 10;6(5):174-8. doi: 10.5306/wjco.v6.i5.174.

32.

Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer.

Kluth M, Ahrary R, Hube-Magg C, Ahmed M, Volta H, Schwemin C, Steurer S, Wittmer C, Wilczak W, Burandt E, Krech T, Adam M, Michl U, Heinzer H, Salomon G, Graefen M, Koop C, Minner S, Simon R, Sauter G, Schlomm T.

Oncotarget. 2015 Sep 29;6(29):27966-79. doi: 10.18632/oncotarget.4626. Erratum in: Oncotarget. 2017 Jan 10;8(2):3761.

33.

8p deletion is strongly linked to poor prognosis in breast cancer.

Lebok P, Mittenzwei A, Kluth M, Özden C, Taskin B, Hussein K, Möller K, Hartmann A, Lebeau A, Witzel I, Mahner S, Wölber L, Jänicke F, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Terracciano L, Krech R, von der Assen A, Müller V, Burandt E.

Cancer Biol Ther. 2015;16(7):1080-7. doi: 10.1080/15384047.2015.1046025. Epub 2015 May 11.

34.

Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: a TMA-based immunohistochemical study on 2,197 breast cancer patients.

Burandt E, Bari Noubar T, Lebeau A, Minner S, Burdelski C, Jänicke F, Müller V, Terracciano L, Simon R, Sauter G, Wilczak W, Lebok P.

Oncol Rep. 2014 Dec;32(6):2628-34. doi: 10.3892/or.2014.3523. Epub 2014 Oct 1.

PMID:
25270339
35.

MALDI imaging-based identification of prognostically relevant signals in bladder cancer using large-scale tissue microarrays.

Steurer S, Singer JM, Rink M, Chun F, Dahlem R, Simon R, Burandt E, Stahl P, Terracciano L, Schlomm T, Wagner W, Höppner W, Omidi M, Kraus O, Kwiatkowski M, Doh O, Fisch M, Soave A, Sauter G, Wurlitzer M, Schlüter H, Minner S.

Urol Oncol. 2014 Nov;32(8):1225-33. doi: 10.1016/j.urolonc.2014.06.007. Epub 2014 Aug 15.

PMID:
25131659
36.
37.

Cyclin D1 gene amplification is highly homogeneous in breast cancer.

Burandt E, Grünert M, Lebeau A, Choschzick M, Quaas A, Jänicke F, Müller V, Scholz U, Bokemeyer C, Petersen C, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Wilczak W.

Breast Cancer. 2016 Jan;23(1):111-119. doi: 10.1007/s12282-014-0538-y. Epub 2014 May 27.

PMID:
24862872
38.

MALDI imaging on tissue microarrays identifies molecular features associated with renal cell cancer phenotype.

Steurer S, Seddiqi AS, Singer JM, Bahar AS, Eichelberg C, Rink M, Dahlem R, Huland H, Sauter G, Simon R, Minner S, Burandt E, Stahl PR, Schlomm T, Wurlitzer M, Schlüter H.

Anticancer Res. 2014 May;34(5):2255-61.

PMID:
24778028
39.

[Invasive breast cancer: the current WHO classification].

Lebeau A, Kriegsmann M, Burandt E, Sinn HP.

Pathologe. 2014 Feb;35(1):7-17. doi: 10.1007/s00292-013-1841-7. Review. German.

PMID:
24496990
41.

Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice.

Burandt E, Schreiber M, Stein A, Minner S, Clauditz TS, Bokemeyer C, Jänicke F, Fisch M, Izbicki JR, Knecht R, Sauter G, Stahl PR.

Genes Chromosomes Cancer. 2014 Mar;53(3):228-39. doi: 10.1002/gcc.22130. Epub 2013 Dec 5.

PMID:
24311521
42.

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, Bandos H, Gavin PG, Fumagalli D, Goldstein LC, Sneige N, Burandt E, Taniyama Y, Bohn OL, Lee A, Kim SI, Reilly ML, Remillard MY, Blackmon NL, Kim SR, Horne ZD, Rastogi P, Fehrenbacher L, Romond EH, Swain SM, Mamounas EP, Wickerham DL, Geyer CE Jr, Costantino JP, Wolmark N, Paik S.

J Natl Cancer Inst. 2013 Dec 4;105(23):1782-8. doi: 10.1093/jnci/djt321. Epub 2013 Nov 21.

43.

MALDI imaging on large-scale tissue microarrays identifies molecular features associated with tumour phenotype in oesophageal cancer.

Quaas A, Bahar AS, von Loga K, Seddiqi AS, Singer JM, Omidi M, Kraus O, Kwiatkowski M, Trusch M, Minner S, Burandt E, Stahl P, Wilczak W, Wurlitzer M, Simon R, Sauter G, Marx A, Schlüter H.

Histopathology. 2013 Oct;63(4):455-62. doi: 10.1111/his.12193. Epub 2013 Jul 16.

PMID:
23855813
44.

Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis.

Katt J, Schwinge D, Schoknecht T, Quaas A, Sobottka I, Burandt E, Becker C, Neurath MF, Lohse AW, Herkel J, Schramm C.

Hepatology. 2013 Sep;58(3):1084-93. doi: 10.1002/hep.26447. Epub 2013 Jul 30.

PMID:
23564624
45.

HER2 amplification in squamous cell carcinomas of the vulva.

Choschzick M, Hess S, Grob T, Burandt E, Wölber L, Simon R, Sauter G.

Histopathology. 2013 May;62(6):965-7. doi: 10.1111/his.12090. Epub 2013 Feb 28. No abstract available.

PMID:
23444903
46.

Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer.

Burandt E, Jens G, Holst F, Jänicke F, Müller V, Quaas A, Choschzick M, Wilczak W, Terracciano L, Simon R, Sauter G, Lebeau A.

Breast Cancer Res Treat. 2013 Feb;137(3):745-53. doi: 10.1007/s10549-013-2406-4. Epub 2013 Jan 16.

PMID:
23322234
47.

Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma.

Minner S, Rump D, Tennstedt P, Simon R, Burandt E, Terracciano L, Moch H, Wilczak W, Bokemeyer C, Fisch M, Sauter G, Eichelberg C.

Cancer. 2012 Mar 1;118(5):1268-75. doi: 10.1002/cncr.26436.

48.

Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma.

Eichelberg C, Minner S, Isbarn H, Burandt E, Terracciano L, Moch H, Kell A, Heuer R, Chun FK, Sauter G, Fisch M, Tennstedt P.

World J Urol. 2013 Aug;31(4):847-53. doi: 10.1007/s00345-011-0783-z. Epub 2011 Oct 19.

PMID:
22009118
49.

[HER2 ASCO guidelines. The answer to everything?].

Burandt E, Sauter G.

Pathologe. 2010 Oct;31 Suppl 2:285-91. doi: 10.1007/s00292-010-1348-4. German.

PMID:
20740285
50.

Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers.

Marx AH, Burandt EC, Choschzick M, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Atanackovic D, Bokemeyer C, Fiedler W, Terracciano L, Sauter G, Izbicki JR.

Hum Pathol. 2010 Nov;41(11):1577-85. doi: 10.1016/j.humpath.2010.02.018. Epub 2010 Jul 24.

PMID:
20656317

Supplemental Content

Loading ...
Support Center